Abstract:Objective To observe the efficacy of combined treatment with cinacalcet, calcitriol, and lanthanum carbonate in uremia patients undergoing hemodialysis (HD) with secondary hyperparathyroidism (SHPT). Methods From January 2020 to December 2022, 80 uremia patients under HD with SHPT treated at Huangshan City People's Hospital were selected. They were randomly divided into the control group (40 cases, treated with calcitriol) and the study group (40 cases, treated with a combination of cinacalcet, calcitriol, and lanthanum carbonate). The calcium-phosphorus product, intact parathyroid hormone (iPTH), parathyroid volume, and carotid intima-media thickness (IMT), as well as adverse reactions, were compared between the two groups. Results Compared with before treatment, both groups showed a decrease in calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Moreover, compared with the control group, the study group had lower calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Compared with before treatment, both groups showed a reduction in parathyroid volume after 1, 3, and 6 months of treatment (P＜0.05). The study group also showed a reduction in carotid IMT after 3 and 6 months of treatment (P＜0.05), while the control group showed a reduction in IMT after 6 months of treatment (P＜0.05). Furthermore, compared with the control group, the study group had lower parathyroid volume and IMT after 3 and 6 months of treatment (P＜0.05). The incidence of adverse reactions in the study group was 17.50%, which was not significantly different from the 15.00% in the control group (χ²=0.092, P=0.762). Conclusion For uremia patients under HD accompanied by SHPT, combined treatment of cinacalcet, calcitriol, and lanthanum carbonate can improve calcium and phosphorus metabolism, regulate iPTH, reduce parathyroid volume and the risk of carotid atherosclerosis, without increasing adverse reactions.